Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Nanjing Biosion Forms ADC Discovery Collaboration with Boston’s ImmunoGen

publication date: Dec 13, 2022

Nanjing Biosion formed an exploratory research collaboration with Boston’s ImmunoGen to create antibody-drug conjugates for solid tumor cancers. To generate the novel drug candidates, Biosion will apply its proprietary SynTracer® high-throughput endocytosis platform, and ImmunoGen will provide its proprietary linker-payload technology. Both companies will specify targets of interest. Biosion is a clinical-stage biotech that develops antibody-based therapies for immune and oncology indications. More details....

Stock Symbol: (NSDQ: IMGN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital